Methyl N-δ-benzyloxycarbonyl-L-ornithinate | 62631-17-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl N-δ-benzyloxycarbonyl-L-ornithinate
• 英文别名: (S)-2-amino-5-benzyloxycarbonylaminopentanoic acid methyl ester；methyl N^δ-(benzyloxycarbonyl)-L-ornithinate；(S)-methyl 2-amino-5-(((benzyloxy)carbonyl)amino)pentanoate；methyl (S)-2-amino-5-(((benzyloxy)carbonyl)amino)pentanoate；methyl 2-amino-5-(((benzyloxy)carbonyl)amino)pentanoate；methyl N^δ-Cbz-L-ornithinate；(S)-2-Amino-5-benzyloxycarbonylamino-pentanoic acid methyl ester；methyl (2S)-2-amino-5-(phenylmethoxycarbonylamino)pentanoate
• CAS: 62631-17-8
• 化学式: C₁₄H₂₀N₂O₄
• 分子量: 280.324
• InChiKey: BJNJTVSXZUTHRA-LBPRGKRZSA-N

物化性质

• 熔点：
  140-141 °C
• 沸点：
  433.0±45.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Methyl N-δ-benzyloxycarbonyl-L-ornithinate 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 生成 N^α-Tosyl-l-ornithinmethylester
  参考文献：
  名称：

  Beta-amino acid derivatives as orally active non-peptide fibrinogen receptor antagonists

  摘要：

  The ornithine sulfonamide 1 was identified by random screening as weak fibrinogen receptor antagonist. Homologation of the carboxylic acid function and further structure activity studies led to the development of novel beta-amino acid derivatives, which are potent and orally active antagonists of the platelet fibrinogen receptor GPIIb/IIIa. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00095-4
• 作为产物：
  描述：

  L-鸟氨酸盐酸盐 在 盐酸 作用下， 生成 Methyl N-δ-benzyloxycarbonyl-L-ornithinate
  参考文献：
  名称：

  某些3-酰基氨基-2-哌啶酮的合成与质谱

  摘要：

  合成了许多在酰基残基中具有羟基，氧代或乙烯基的3-酰基氨基-2-哌啶酮。通过氘化类似物的研究，研究了电子撞击3-（3-羟基丁酰氨基）-2-哌啶酮的主要碎片离子形成的机理。

  DOI：

  10.1039/j39710003743

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Synthesis, anti-tuberculosis activity and 3D-QSAR study of amino acid conjugates of 4-(adamantan-1-yl) group containing quinolines
  作者：Amit Nayyar、Sanjay R. Patel、Mushtaque Shaikh、Evans Coutinho、Rahul Jain

  DOI：10.1016/j.ejmech.2008.10.004

  日期：2009.5

  The synthesis, antimycobacterial activity and 3D-QSAR study of two series of 4-(adamantan-1-yl) group containing quinolines conjugated to amino acids are described. The most potent analogs displayed in vitro antimycobacterial activity ranging between 1.00 and 3.125 μg/mL. To understand the relationship between structure and activity, a 3D-QSAR analysis has been carried out by Comparative Molecular

  描述了两个系列的4-（金刚烷-1-基）基团与氨基酸缀合的喹啉的合成，抗分枝杆菌活性和3D-QSAR研究。最有效的类似物在1.00和3.125μg/ mL之间显示出体外抗分枝杆菌活性。为了了解结构和活性之间的关系，已通过比较分子场分析（CoMFA）进行了3D-QSAR分析。通过场对准生成的CoMFA模型很好地预测了测试集中分子的活性。使用原子拟合比对可获得最佳模型。基于分子领域，结构和活性之间的关系很容易理顺。
• Relationship between Structure and Papain Inhibitory Activity of Epoxysuccinyl Amino Acid Derivatives
  作者：Masaharu Tamai、Takashi Adachi、Kiyoshi Oguma、Shigeo Morimoto、Kazunori Hanada、Sadafumi Ohmura、Masahiro Ohzeki

  DOI：10.1080/00021369.1981.10864575

  日期：1981.3

  A number of amino acid derivatives of DL-Zra/w-epoxysuccinic acid, with a general formula of R1O-ES-AA-OR2 (ES, DL-trans-epoxysuccinyl group; AA, amino acid residue) were newly synthesized and used for the study of structure-activity relationships of papain inhibition. Branched-alkyl amino acids, such as Leu, He and Val, as AA and hydrogen or an alkyl group substituted with a phenyl or cycloalkyl group as R1 were desirable for activity, respectively. However, R2 or the optical activities of ES and AA not so much influenced on the activity.

  一些DL-Zra/w-环氧琥珀酸氨基酸衍生物被新合成并用于木瓜蛋白酶抑制的结构-活性关系研究。通式为R1O-ES-AA-OR2（ES，DL-反式环氧琥珀酰基团；AA，氨基酸残基）。AA为支链烷基氨基酸，如Leu、He和Val，R1为氢或被苯基或环烷基取代的烷基，这类衍生物具有较好的活性。但R2或ES和AA的光学活性对活性的影响不大。
• A synthetic approach to 5/5/6-polycyclic tetramate macrolactams of the discodermide type
  作者：Kevin Bodenschatz、Julia Stöckl、Markus Winterer、Rainer Schobert

  DOI：10.1016/j.tet.2021.132113

  日期：2022.1

  A flexible synthetic route to the 16-membered tetramate-embedding macrocyclic scaffold present in various polycyclic tetramate macrolactams (PTMs) was developed which differs from the seminal synthesis of ikarugamycin by Boeckman Jr. in protecting groups and the order of connections. We also devised a short approach to various stereoisomers of the 5/5/6-tricarbocyclic motif found in discodermide and

  开发了一种灵活的合成路线，用于存在于各种多环四甲酸大环内酰胺 (PTM) 中的 16 元四甲酸嵌入大环支架，其在保护基团和连接顺序方面不同于 Boeckman Jr. 对伊卡鲁霉素的精髓合成。从 Weiss 的二酮开始，我们还设计了一种简短的方法来处理在 discoderide 和其他 PTM 中发现的 5/5/6-三碳环基序的各种立体异构体。